Adding Sodium-Glucose Co-Transporter 2 Inhibitors to Sulfonylureas and Risk of Hypoglycemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2021 Nov 8

PMID 34744998

Authors

Meng Jiang

Qiaoshu Liu

Tiejian Jiang

Paul Nizigiyimana

Minxiang Lei

Affiliations

Soon will be listed here.

Abstract

Background: Hypoglycemia is an important event that could be related to increased mortality in patients with diabetes. The risk of hypoglycemia is not clearly illustrated to increase when Sodiumglucose co-transporter 2 (SGLT-2) inhibitors are used concomitantly with sulfonylureas. The present study will assess the risk of hypoglycemia associated with the concomitant use of SGLT-2 inhibitors and sulfonylureas compared with placebo and sulfonylureas.

Method: We searched Medline, EMBASE, Cochrane Central Register of Controlled Trials, and Clinicaltrial.gov and identified the randomized trials comparing SGLT-2 inhibitors with placebo for type 2 diabetes treated with sulfonylureas. The risk of bias in each trial was assessed using the Cochrane tool. The risk ratio of hypoglycemia was measured using the Mantel Haenszel method. We also performed subgroup analysis to examine the dosage effects. The number needed to harm (NNH) was measured according to the duration of intervention.

Results: A total of 12 studies, including 3761 participants, were enrolled in our systematic review and meta-analysis. The risk ratio of hypoglycemia was 1.67 (95% CI 1.42 to 1.97). The NNH was 13 (95% CI 9 to 21) for a treatment duration of 24 weeks or less, 11 (8 to 18) for 25 to 48 weeks, and 7 (5 to 10) for more than 48 weeks. Subgroup analysis showed that no difference was found between higher and lower doses of SGLT-2 inhibitors. The risk ratio related to lower dose SGLT-2 inhibitors was 1.56 (95% CI 1.30 to 1.88), and the risk ratio related to higher dose SGLT-2 inhibitors was 1.70 (95% CI 1.42 to 2.04).

Conclusions: The risk of hypoglycemia was significantly increased in subjects treated with SGLT-2 inhibitors compared with placebo. Addition of SGLT-2 inhibitors to sulfonylureas would lead to one more case of hypoglycemia in every 13 patients with a treatment duration less than 24 weeks. This suggests that a decrease in sulfonylureas dose may be an important recommendation when adding SGLT-2 inhibitors to sulfonylureas.

References

Hemmingsen B, Lund S, Gluud C, Vaag A, Almdal T, Hemmingsen C . Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ. 2011; 343:d6898. PMC: 3223424. DOI: 10.1136/bmj.d6898. View

Fulcher G, Matthews D, Perkovic V, de Zeeuw D, Mahaffey K, Weiss R . Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. Diabetes Ther. 2015; 6(3):289-302. PMC: 4575303. DOI: 10.1007/s13300-015-0117-z. View

Graveling A, Frier B . Hypoglycaemia: an overview. Prim Care Diabetes. 2009; 3(3):131-9. DOI: 10.1016/j.pcd.2009.08.007. View

Seino Y, Inagaki N, Haneda M, Kaku K, Sasaki T, Fukatsu A . Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2015; 6(4):443-53. PMC: 4511304. DOI: 10.1111/jdi.12316. View

Lipska K, Ross J, Wang Y, Inzucchi S, Minges K, Karter A . National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. JAMA Intern Med. 2014; 174(7):1116-24. PMC: 4152370. DOI: 10.1001/jamainternmed.2014.1824. View

Graveling A, Frier B . Impaired awareness of hypoglycaemia: a review. Diabetes Metab. 2011; 36 Suppl 3:S64-74. DOI: 10.1016/S1262-3636(10)70470-5. View

van Baar M, van Ruiten C, Muskiet M, van Bloemendaal L, IJzerman R, van Raalte D . SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. Diabetes Care. 2018; 41(8):1543-1556. DOI: 10.2337/dc18-0588. View

Haring H, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle H . Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013; 36(11):3396-404. PMC: 3816918. DOI: 10.2337/dc12-2673. View

. Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1-5, 2012. Berlin, Germany. Diabetologia. 2012; 55 Suppl 1:S7-537. DOI: 10.1007/s00125-012-2688-9. View

10.

Huang E, Laiteerapong N, Liu J, John P, Moffet H, Karter A . Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study. JAMA Intern Med. 2013; 174(2):251-8. PMC: 3950338. DOI: 10.1001/jamainternmed.2013.12956. View

11.

de Wit H, Te Groen M, Rovers M, Tack C . The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016; 82(1):301-14. PMC: 4917794. DOI: 10.1111/bcp.12925. View

12.

Blonde L, Stenlof K, Fung A, Xie J, Canovatchel W, Meininger G . Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgrad Med. 2016; 128(4):371-80. DOI: 10.1080/00325481.2016.1169894. View

13.

Strojek K, Pandey A, Dell V, Sisson M, Wang S, Huyck S . Efficacy and Safety of Ertugliflozin in Patients With Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy: a Substudy of VERTIS CV. Diabetes Ther. 2021; 12(4):1175-1192. PMC: 7994479. DOI: 10.1007/s13300-021-01018-w. View

14.

Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S . Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care. 2015; 38(3):365-72. DOI: 10.2337/dc14-0666. View

15.

Ji L, Han P, Liu Y, Yang G, Dieu Van N, Vijapurkar U . Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea. Diabetes Obes Metab. 2014; 17(1):23-31. DOI: 10.1111/dom.12385. View

16.

Barnett A, Mithal A, Manassie J, Jones R, Rattunde H, Woerle H . Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014; 2(5):369-84. DOI: 10.1016/S2213-8587(13)70208-0. View

17.

Yale J, Bakris G, Cariou B, Nieto J, David-Neto E, Yue D . Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014; 16(10):1016-27. DOI: 10.1111/dom.12348. View

18.

Yang X, Lai D, Zhong X, Shen H, Huang Y . Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. Eur J Clin Pharmacol. 2014; 70(10):1149-58. DOI: 10.1007/s00228-014-1730-x. View

19.

Cefalu W, Leiter L, de Bruin T, Gause-Nilsson I, Sugg J, Parikh S . Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension. Diabetes Care. 2015; 38(7):1218-27. PMC: 4831907. DOI: 10.2337/dc14-0315. View

20.

Takahashi K, Cho K, Nakamura A, Miya A, Miyoshi A, Yamamoto C . Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes. J Diabetes Investig. 2018; 10(2):429-438. PMC: 6400155. DOI: 10.1111/jdi.12913. View